These results indicate that the nuclear expression of CD133 may predict advanced malignancy for patients with endometrial cancer, as CD133 expression in the nucleus and plasma membrane is positively and negatively associated, respectively, with a higher grade and FIGO stages, as well as more intense angioinvasion. Here, PROM1 is linked to endometrial cancer.